News articles about Apollo Endosurgery (NASDAQ:APEN) have been trending somewhat negative this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apollo Endosurgery earned a daily sentiment score of -0.01 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.3276115403221 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Apollo Endosurgery : Five dead after FDA-approved obesity treatment (4-traders.com)
- FDA: Deaths Following Intragastric Balloon Placement for Obesity (elcumanes.com)
- Apollo endosurgery clarifies FDA letter on intragastric balloon safety (medicaldevicedaily.com)
- Apollo Endosurgery Inc: Bounces back from record low (timesofindia.indiatimes.com)
Several research analysts have issued reports on APEN shares. ValuEngine downgraded shares of Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. Roth Capital started coverage on shares of Apollo Endosurgery in a research report on Wednesday, August 2nd. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Craig Hallum started coverage on shares of Apollo Endosurgery in a report on Monday, July 24th. They issued a “buy” rating and a $11.00 target price on the stock.
Shares of Apollo Endosurgery (NASDAQ APEN) traded down 1.15% during mid-day trading on Friday, hitting $4.29. 709,218 shares of the stock traded hands. The stock’s market cap is $74.01 million. The firm’s 50 day moving average price is $6.17 and its 200-day moving average price is $8.65. Apollo Endosurgery has a 12-month low of $3.77 and a 12-month high of $22.27.
Apollo Endosurgery (NASDAQ:APEN) last released its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.40. The firm had revenue of $17.14 million for the quarter. Apollo Endosurgery had a negative return on equity of 142.98% and a negative net margin of 81.59%. Analysts predict that Apollo Endosurgery will post ($2.18) earnings per share for the current year.
In related news, major shareholder Holdings A/S Novo sold 50,130 shares of the stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $6.90, for a total value of $345,897.00. Following the completion of the transaction, the insider now owns 1,334,772 shares in the company, valued at approximately $9,209,926.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Todd Newton acquired 136,363 shares of Apollo Endosurgery stock in a transaction dated Tuesday, July 25th. The shares were acquired at an average price of $5.50 per share, with a total value of $749,996.50. Following the transaction, the chief executive officer now owns 167,129 shares in the company, valued at approximately $919,209.50. The disclosure for this purchase can be found here. Insiders purchased a total of 1,277,271 shares of company stock valued at $7,024,991 in the last quarter. 74.20% of the stock is currently owned by insiders.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related companies with MarketBeat.com's FREE daily email newsletter.